Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experience.
hepatitis C
immunosuppression
kidney function
kidney transplantation
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
26
09
2020
revised:
05
11
2020
accepted:
14
11
2020
pubmed:
3
12
2020
medline:
16
10
2021
entrez:
2
12
2020
Statut:
ppublish
Résumé
Hepatitis C virus (HCV) infection has detrimental effects on patient and graft survival after kidney transplantation. In the pre-direct-acting antiviral (DAA) era, treatment of HCV infection was associated with low response rates, poor tolerance, and increased risk of allograft rejection. However, DAAs have revolutionized HCV treatment. The aims of this study were to determine the impact of DAA on the sustained virologic response (SVR), renal function, and calcineurin inhibitor (CNI) levels and assess the tolerability to treatment in kidney transplant recipients with HCV infection in Qatar. This retrospective study included the medical records of all kidney transplant recipients with confirmed HCV infection before January 1, 2020. All data were obtained from the patients' electronic medical records; these included patient demographics; virologic responses to treatment; serum creatinine levels during treatment; urine protein to creatinine ratios and CNI levels before, during, and after treatment; and side effects related to DAA therapy. A total of 27 kidney transplant recipients with HCV were identified, 23 of whom received DAA therapy. The length of treatment ranged from 12 to 24 weeks, and 52% of patients had HCV genotype 1 infection. The median log10 HCV RNA was 6.6 copies per milliliter. None of the patients had liver cirrhosis, and all of them achieved SVR. There was no statistically significant difference in the glomerular filtration rate before, during, and after treatment. Most patients had stable CNI trough levels during treatment and did not require dose adjustment. HCV infection was successfully eradicated by DAA therapy in kidney transplant recipients, with a 100% SVR rate. Moreover, DAA therapy was well-tolerated, and kidney function remained stable without an increased risk of rejection. These results are expected to drive the eradication of hepatitis C from the entire country.
Identifiants
pubmed: 33264509
doi: 10.1002/iid3.386
pmc: PMC7860605
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
246-254Informations de copyright
© 2020 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Hepatology. 2018 Oct;68(4):1298-1307
pubmed: 29672891
East Mediterr Health J. 2019 Jul 24;25(5):362-365
pubmed: 31364761
Transplantation. 2004 Sep 15;78(5):745-50
pubmed: 15371680
J Chin Med Assoc. 2020 Jan;83(1):18-24
pubmed: 31714442
Biomed Res Int. 2019 Apr 7;2019:4674560
pubmed: 31179323
J Transl Int Med. 2017 Mar 31;5(1):8-17
pubmed: 28680834
Transplantation. 1995 Oct 27;60(8):799-805
pubmed: 7482738
Ann Intern Med. 2017 Jan 17;166(2):109-117
pubmed: 27842383
Am J Transplant. 2016 May;16(5):1474-9
pubmed: 26587971
World J Hepatol. 2017 Dec 28;9(36):1352-1360
pubmed: 29359019
Transpl Int. 2018 Aug;31(8):887-899
pubmed: 29356211
Liver Int. 2018 Aug;38(8):1411-1417
pubmed: 29271562
Int J Antimicrob Agents. 2017 Mar;49(3):379-382
pubmed: 28185946
Transplant Direct. 2019 Nov 18;5(12):e510
pubmed: 32095505
Immun Inflamm Dis. 2021 Mar;9(1):246-254
pubmed: 33264509
Kidney Int. 2018 Mar;93(3):560-567
pubmed: 29325996
Am J Transplant. 2016 May;16(5):1588-95
pubmed: 26604182
Semin Dial. 2019 Mar;32(2):187-195
pubmed: 30496617
Ther Apher Dial. 2020 Apr;24(2):184-188
pubmed: 31290282
Clin Transplant. 2017 May;31(5):
pubmed: 28239909
Liver Transpl. 2015 Jun;21(6):823-30
pubmed: 25825070
Int Urol Nephrol. 2019 Dec;51(12):2243-2254
pubmed: 31612423
Rev Med Virol. 2008 Mar-Apr;18(2):97-115
pubmed: 18064722
N Engl J Med. 2020 Mar 19;382(12):1166-1174
pubmed: 32187475
Kidney Int. 2016 May;89(5):988-994
pubmed: 27083277
Int Urol Nephrol. 2019 Dec;51(12):2295-2304
pubmed: 31531807
Am J Kidney Dis. 1998 Oct;32(4):629-34
pubmed: 9774125
Aliment Pharmacol Ther. 2017 Jan;45(1):150-159
pubmed: 27813162
Transpl Infect Dis. 2018 Feb;20(1):
pubmed: 29111569
Transplantation. 2018 Mar;102(3):454-460
pubmed: 28976413
Kidney Int Suppl. 2008 Apr;(109):S1-99
pubmed: 18382440
Clin Pharmacokinet. 2016 Feb;55(2):197-208
pubmed: 26353895
Am J Kidney Dis. 2004 Jan;43(1):131-9
pubmed: 14712436
Transpl Int. 2017 Sep;30(9):865-873
pubmed: 28332729
Saudi J Kidney Dis Transpl. 1999 Jan-Mar;10(1):31-5
pubmed: 18212411
Hepatology. 1999 Jan;29(1):257-63
pubmed: 9862875